What are the FIB‑4 (Fibrosis‑4) index result ranges and their clinical interpretation for an adult patient with a history of alcohol use?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 27, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

FIB-4 Index Ranges for Alcoholic Patients

For patients with alcohol-related liver disease (ARLD), use the same FIB-4 thresholds as for NAFLD: <1.3 (or <2.0 if age >65) indicates low risk of advanced fibrosis and can be managed in primary care, while FIB-4 of 1.3-3.25 represents indeterminate risk requiring further testing, and FIB-4 >3.25 indicates high risk requiring hepatology referral. 1

Age-Stratified Interpretation

The FIB-4 index must be interpreted differently based on patient age:

For patients <65 years old:

  • FIB-4 <1.3: Low risk - excludes advanced fibrosis with 90-95% negative predictive value 2, 1

    • Manage in primary care with lifestyle modification
    • Repeat testing in 2-3 years if risk factors persist 2

  • FIB-4 1.3-3.25: Indeterminate risk - requires second-line testing

    • Proceed to elastography (FibroScan/ARFI) or Enhanced Liver Fibrosis (ELF) test 1
    • This range captures 30-40% of patients 2

  • FIB-4 >3.25: High risk - 60-80% positive predictive value for advanced fibrosis 2

    • Refer to hepatology for confirmation with elastography or biopsy 2

For patients ≥65 years old:

  • FIB-4 <2.0: Low risk threshold (adjusted upward due to age effect on calculation) 1
  • FIB-4 2.0-3.25: Indeterminate - requires further testing
  • FIB-4 >3.25: High risk - hepatology referral indicated

Critical Considerations for Alcoholic Patients

Active Drinking and AST Elevation

A crucial caveat: If AST is >2x upper limit of normal, FIB-4 may give falsely elevated results due to acute alcoholic hepatitis rather than fibrosis 3. In these cases:

  • Repeat FIB-4 after at least 1 week of abstinence or reduced drinking
  • Retest biochemical markers in parallel
  • AST elevation correlates with active alcohol-induced inflammation, not necessarily fibrosis 3

Alcohol Consumption Thresholds

The guidelines define harmful drinking levels that trigger fibrosis assessment 1:

  • Women: ≥35 units/week
  • Men: ≥50 units/week

For patients drinking at these levels, liver fibrosis assessment with FIB-4 is the critical next step 1.

GGT as Additional Risk Marker

Patients with GGT >100 U/L (or especially ≥200 U/L) warrant particular attention, as this substantially increases risk even with moderate FIB-4 elevation 1, 4. The combination of elevated FIB-4 and GGT ≥200 U/L showed a hazard ratio of 7.65 for developing advanced fibrosis 4.

Comparison with Elastography

When FIB-4 indicates need for further testing, elastography cutoffs for ARLD are 1:

  • <8 kPa: Does not exclude early disease but low risk
  • 8-16 kPa: Possible advanced fibrosis - consider hepatology referral if still drinking harmfully
  • >16 kPa: Possible cirrhosis - refer to hepatology

Clinical Pitfalls to Avoid

  1. Don't use lower age-adjusted threshold (<2.0) for patients under 65 - this significantly reduces sensitivity and misses cases 5. The data show age modification of FIB-4 at the 1.3 threshold is minimal and doesn't warrant adjustment 5.

  2. Don't interpret FIB-4 in isolation when AST is markedly elevated - wait for biochemical stabilization after brief abstinence 3

  3. Don't discharge patients with FIB-4 >1.3 without second-line testing - approximately 30-40% fall in the indeterminate zone requiring elastography or ELF 2

  4. Recognize that alcohol use disorder with mental health comorbidities is associated with lower hepatology referral rates despite elevated FIB-4, representing a care gap that needs active correction 6

Calculation Formula

FIB-4 = (Age × AST) / (Platelet count × √ALT)

Where:

  • Age in years
  • AST in IU/L
  • Platelet count in 10⁹/L
  • ALT in IU/L

1

References

Related Questions

What are the diagnostic criteria for metabolic dysfunction-associated steatohepatitis (MASH)?
Interpret the liver ultrasound with Doppler and shear‑wave elastography findings in a 53‑year‑old female with a Fib‑4 score of 1.4, showing mild hepatomegaly and fatty infiltration.
What does a Fibrosis‑4 (FIB‑4) score of 3.37 indicate and how should it be managed?
What is the Fibrosis‑4 (FIB‑4) index, how is it calculated, and how are its results interpreted?
In a 35-year-old patient with a platelet count of 154 ×10⁹/L, is this value normal and does it warrant further evaluation for liver disease (e.g., calculation of the FIB‑4 score)?
What is the minimum inhibitory concentration (MIC) breakpoint for ceftazidime‑avibactam against Pseudomonas aeruginosa?
What is the target INR range and how should INR be managed in a patient with a mechanical heart valve replacement and atrial fibrillation?
What is the appropriate management of urinary retention in a patient with Parkinson's disease?
What is the most likely diagnosis for chest pain that is relieved by rest?
What is the HScore, how is it calculated, and how is it used to estimate the probability of haemophagocytic lymphohistiocytosis (HLH)?
Can ciprofloxacin‑dexamethasone ear drops be given when the tympanic membrane is not visualized due to cerumen obstruction?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.